Novartis AG

Novartis AG (https://www.novartis.com/) is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

• Lucrarile de constructii in luna iulie - 19 septembrie 2024
• Fidelis pierde din popularitate - 05 octombrie 2023
• Mai putine locuinte date in folosinta - 13 iunie 2023
• Novartis vrea un spin off cu Sandoz pentru a crea un lider european pentru medicamente generice - 25 august 2022
• Novartis demareaza un nou program de buybacks - 13 martie 2023
• Novartis Leaning Toward Spinoff of $25 Billion Generics Arm - 01 iulie 2022
• Novartis Allows Generic Leukemia Drug Production in Seven Nations - 20 octombrie 2022
• Novartis (US.NVS) sees steady growth as weighs selling generics arm - 02 februarie 2022
• Novartis (US.NVS) reduce numarul locurilor de munca - 12 aprilie 2022
• Start subscrieri Fidelis - 28 martie 2023